Trajan Wealth LLC Raises Position in Elevance Health, Inc. $ELV

Trajan Wealth LLC grew its position in shares of Elevance Health, Inc. (NYSE:ELV) by 17.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 86,271 shares of the company’s stock after acquiring an additional 12,846 shares during the period. Elevance Health comprises about 1.2% of Trajan Wealth LLC’s holdings, making the stock its 22nd largest holding. Trajan Wealth LLC’s holdings in Elevance Health were worth $27,876,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Equitable Trust Co. boosted its position in shares of Elevance Health by 0.9% during the third quarter. Equitable Trust Co. now owns 8,011 shares of the company’s stock valued at $2,589,000 after purchasing an additional 68 shares in the last quarter. Vulcan Value Partners LLC raised its holdings in Elevance Health by 42.7% in the third quarter. Vulcan Value Partners LLC now owns 419,195 shares of the company’s stock worth $135,706,000 after purchasing an additional 125,464 shares in the last quarter. Vestmark Advisory Solutions Inc. lifted its position in Elevance Health by 79.6% during the third quarter. Vestmark Advisory Solutions Inc. now owns 3,371 shares of the company’s stock valued at $1,089,000 after buying an additional 1,494 shares during the period. Channing Capital Management LLC boosted its holdings in shares of Elevance Health by 32.6% during the 3rd quarter. Channing Capital Management LLC now owns 36,049 shares of the company’s stock valued at $11,648,000 after buying an additional 8,861 shares in the last quarter. Finally, Michels Family Financial LLC purchased a new stake in shares of Elevance Health in the 3rd quarter worth about $745,000. Institutional investors own 89.24% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on ELV shares. Leerink Partners increased their price target on shares of Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research note on Thursday, January 29th. Sanford C. Bernstein cut their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, TD Cowen restated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Trading Down 1.5%

Shares of NYSE ELV opened at $342.95 on Monday. The firm’s 50 day moving average price is $352.37 and its 200-day moving average price is $334.71. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The company has a market cap of $75.69 billion, a PE ratio of 13.65, a P/E/G ratio of 1.90 and a beta of 0.50.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is 27.23%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.